Literature DB >> 16044020

Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity.

Mothanje Barbara Lucia, Caterina Golotta, Sergio Rutella, Elena Rastrelli, Andrea Savarino, Roberto Cauda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16044020

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  9 in total

1.  Quantitative immunoassay to measure plasma and intracellular atazanavir levels: analysis of drug accumulation in cultured T cells.

Authors:  Camille Roucairol; Stéphane Azoulay; Marie-Claire Nevers; Christophe Créminon; Thibault Lavrut; Rodolphe Garraffo; Jacques Grassi; Alain Burger; Danièle Duval
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line.

Authors:  Niladri Chattopadhyay; Jason Zastre; Ho-Lun Wong; Xiao Yu Wu; Reina Bendayan
Journal:  Pharm Res       Date:  2008-05-31       Impact factor: 4.200

Review 3.  Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives.

Authors:  Victoria Tittle; Lauren Bull; Marta Boffito; Nneka Nwokolo
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

4.  Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.

Authors:  Chad J Achenbach; Kristin M Darin; Robert L Murphy; Christine Katlama
Journal:  Future Virol       Date:  2011-02       Impact factor: 1.831

5.  Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).

Authors:  Jose R Castillo-Mancilla; Christina L Aquilante; Michael F Wempe; Laura M Smeaton; Cynthia Firnhaber; Alberto M LaRosa; Nagalingeswaran Kumarasamy; Adriana Andrade; Gautam Baheti; Courtney V Fletcher; Thomas B Campbell; David W Haas; Samantha MaWhinney; Peter L Anderson
Journal:  J Antimicrob Chemother       Date:  2016-02-17       Impact factor: 5.790

6.  Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.

Authors:  Nils von Hentig; Axel Müller; Carsten Rottmann; Timo Wolf; Thomas Lutz; Stephan Klauke; Michael Kurowski; Bruno Oertel; Brenda Dauer; Sebastian Harder; Schlomo Staszewski
Journal:  Antimicrob Agents Chemother       Date:  2007-02-12       Impact factor: 5.191

7.  In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile.

Authors:  Christian Callebaut; Kirsten Stray; Luong Tsai; Matt Williams; Zheng-Yu Yang; Carina Cannizzaro; Stephanie A Leavitt; Xiaohong Liu; Kelly Wang; Bernard P Murray; Andrew Mulato; Marcos Hatada; Tina Priskich; Neil Parkin; Swami Swaminathan; William Lee; Gong-Xin He; Lianhong Xu; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

8.  The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.

Authors:  Tina S Skinner-Adams; Alice S Butterworth; Kimberly A Porter; Ronald D'Amico; Fred Sawe; Doug Shaffer; Abraham Siika; Mina C Hosseinipour; Elizabeth Stringer; Judith S Currier; Tsungai Chipato; Robert Salata; Shahin Lockman; Joseph J Eron; Steven R Meshnick; James S McCarthy
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

9.  Role of atazanavir in the treatment of HIV infection.

Authors:  Pablo Rivas; Judit Morello; Carolina Garrido; Sonia Rodríguez-Nóvoa; Vincent Soriano
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.